Genentech Says FDA Approves Kadcyla for Treatment of Some Breast Cancer Patients

Date : 05/03/2019 @ 8:37PM
Source : Dow Jones News
Stock : Roche Holding (QX) (RHHBY)
Quote : 38.3  0.0 (0.00%) @ 12:00AM

Genentech Says FDA Approves Kadcyla for Treatment of Some Breast Cancer Patients

Roche Holding (QX) (USOTC:RHHBY)
Historical Stock Chart

1 Year : From Nov 2018 to Nov 2019

Click Here for more Roche Holding (QX) Charts.
   By Stephen Nakrosis 

Genentech said on Friday the U.S. Food and Drug Administration approved Kadcyla, or ado-trastuzumab emtansine, for after-surgery treatment of some people with HER2-positive early breast cancer.

Genentech said the FDA based its approval "on data showing Kadcyla cut the risk of disease recurring by half compared to Herceptin in the adjuvant setting for specific patients with HER2-positive early breast cancer."

Genentech said its application was reviewed and approved under the FDA's Real-Time Oncology Review and Assessment Aid pilot programs, leading to an approval 12 weeks after completing the submission.

Genentech is a member of the Roche Group.


--Write to Stephen Nakrosis at


(END) Dow Jones Newswires

May 03, 2019 16:22 ET (20:22 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest RHHBY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.